This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
by Zacks Equity Research
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.
Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data
by Zacks Equity Research
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) CAR T cell therapy has achieved an overall response rate of 83% in patients with Waldenstrom macroglobulinemia.
Wall Street Analysts Think Mustang Bio, Inc. (MBIO) Could Surge 331.15%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 331.2% upside potential for Mustang Bio, Inc. (MBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Mustang Bio, Inc. (MBIO) Could Rally 711.55%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Mustang Bio, Inc. (MBIO) points to a 711.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Mustang Bio, Inc. (MBIO) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Mustang Bio, Inc. (MBIO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Mustang Bio (MBIO) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Mustang Bio (MBIO) has been struggling lately, but the selling pressure may be coming to an end soon.
Is the Options Market Predicting a Spike in Mustang Bio (MBIO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Mustang Bio (MBIO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.
Do Options Traders Know Something About Mustang Bio (MBIO) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.
Mustang Bio (MBIO) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Mustang Bio (MBIO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Do Options Traders Know Something About Mustang Bio (MBIO) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.
Mustang Bio (MBIO) Jumps: Stock Rises 8.2%
by Zacks Equity Research
Mustang Bio (MBIO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Is Mustang (MBIO) Stock a Solid Choice Right Now?
by Zacks Equity Research
Mustang (MBIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Mustang Bio, Inc. (MBIO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Mustang Bio, Inc. (MBIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Mustang Bio Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Mustang Bio has been struggling lately, but the selling pressure may be coming to an end soon.
Mustang Bio, Inc. (MBIO) Enters Oversold Territory
by Zacks Equity Research
Mustang Bio, Inc. (MBIO) Enters Oversold Territory
Mustang Bio (MBIO) is Oversold: Can It Recover?
by Zacks Equity Research
Mustang Bio, Inc. (MBIO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Mustang Bio (MBIO) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Mustang Bio, Inc. (MBIO) has been struggling lately, but the selling pressure may be coming to an end soon